No long-term benefit of adding ipilimumab to pembrolizumab in metastatic NSCLC Presented ByDr Delvys Rodriguez-Abreu, Universidad de Las Palmas de Gran Canaria, Spain TrialPhase 3, KEYNOTE-598 ConferenceELCC 2022 25 May, 2022 12:38
ELCC 2022 Highlights Podcast Presented ByDr Rachel Giles, Medicom ConferenceELCC 2022 19 April, 2022 10:43